Every Question We Get Before the Strategy Call.

ACG reviews your target market, clinic category interest, and background. You leave with a real picture of what the market opportunity looks like in your area, an honest view of the compliance landscape for your state, and clarity on whether this is the right fit. There is no pitch and no hard close. Most people leave with more clarity than they expected in 30 minutes.

ACG works with entrepreneurs who want to build a real, defensible, cash-pay health business — not a side project, and not a get-rich-quick play. Most ACG clients come from business, finance, real estate, corporate careers, and existing healthcare backgrounds. The common thread is that they are serious operators who want to build something that lasts. No medical background is required, but business seriousness is.

That is the first question ACG answers — before you commit to anything. Market validation is the starting point of every ACG engagement: population demographics, income distribution, existing competition, search demand for your specific clinic category, and local regulatory environment. You know whether the opportunity exists before you spend a dollar. Some markets surprise people. Some that look saturated have gaps. Some that look empty don't have the patient base. ACG maps this specifically for you.

Yes. ACG facilitates client introductions for qualified prospects. Ask on the strategy call and we will match you with a client who opened a similar clinic type in a similar market. We don't publish client contact details publicly — the introduction is facilitated by ACG after the strategy call.

No — and this is not a caveat, it is the design. ACG introduces you to a vetted Medical Director who holds prescribing authority and manages the clinical oversight. You own and operate the business. The Medical Director handles the clinical side. Most ACG clinic owners come from business, finance, real estate, and corporate careers with no healthcare background at all.

A Medical Director is a licensed physician (MD or DO) who provides clinical oversight, signs off on treatment protocols, holds the prescribing authority for your clinic's services, and satisfies the medical oversight requirements for your state's regulatory structure. In most models, the Medical Director works on a part-time or supervisory basis — they are not a full-time employee. ACG introduces you to vetted Medical Directors from its network and helps you structure the relationship correctly for your state.

Yes — depending on your clinic type, you will need licensed clinical staff (typically a Nurse Practitioner, PA, or RN) to administer treatments. The specific requirement depends on the services you offer and your state's scope-of-practice rules. ACG helps you identify the right clinical roles for your model, assists with the hiring process, and provides training for your team once they are onboarded.

ACG targets a 60-day launch window from keys received — market and regulatory conditions permitting. This timeline covers entity setup, Medical Director introduction, licensing, supplier onboarding, brand build, website, and marketing launch. Specific timelines vary by state, clinic type, and regulatory complexity. Some states move faster. Some take longer. ACG is transparent about what the realistic timeline looks like for your specific market on the strategy call.

Phase 1 is Vision & Discovery — market validation, competitor mapping, search demand analysis, and a go/no-go before you commit to anything. Phase 2 is Clinic & Staff Setup — entity structure, Medical Director, licensing, EMR, payment processing, brand, website, and staff hiring. Phase 3 is Regenerative Supply — clinical training, supplier access at pre-negotiated rates, lab partners, and protocol setup with MD sign-off. Phase 4 is Launch — brand awareness campaign, local SEO activation across 100+ directories, and paid advertising. Phase 5 is Post-Launch — 60 days of continued ACG advisory including bottleneck identification, marketing diagnosis, and staff follow-up training.

No. ACG's market validation phase helps you identify the right market and location before you commit to a lease. In fact, signing a lease before completing market validation is one of the most common mistakes ACG helps clients avoid. The engagement starts before you find a location — so you can validate demand, understand the competitive landscape, and choose the right area with confidence.

The ACG engagement includes 60 days of post-launch advisory. During this period ACG identifies operational bottlenecks, diagnoses marketing performance, conducts staff follow-up training, and adjusts the launch campaign based on early data. After the post-launch period the clinic is fully yours — no ongoing fees, no royalties, no dependency. ACG also offers separate ongoing optimization engagements for clients who want continued advisory support.

ACG launches clinics across 14 categories: longevity clinic setup, hormone optimization (including TRT and BHRT), men's health and TRT clinic consulting, women's health and hormone clinics, metabolic weight loss with GLP-1, sexual wellness, joint and musculoskeletal regenerative care, peptide therapy, aesthetics and med spa, IV therapy and infusion, neurological wellness, hair regeneration, and telehealth delivery models. If you're not sure which category fits your market and background, the strategy call is where that gets determined.

ACG determines this as part of the market validation process — using population demographics, local competition, search demand by category, and income distribution in your target area. Some markets are strongest for hormone optimization. Others have an underserved peptide therapy demand. Some suburban markets are ideal for metabolic weight loss clinics. The right category is data-driven, not preference-driven. ACG maps it before you commit.

Yes. Longevity clinics — offering NAD+ infusions, peptide protocols, hormone optimization, and regenerative services — are one of the most common ACG launch categories. The business owner does not need clinical credentials. ACG introduces you to a Medical Director, provides clinical training for your staff, and ensures the protocols are properly supervised. You own and operate the business side.

Hormone optimization — including TRT, HRT, and BHRT — is the single highest-volume category in cash-pay regenerative health. Monthly U.S. search volume for TRT-related terms exceeds 246,000. The market is growing at a documented 17% CAGR. Most of the patient demand in this category is currently captured by telehealth apps, not local relationship-based clinics — which is exactly the gap ACG-launched clinics fill.

Peptide therapy is the fastest-growing category in ACG's portfolio. Monthly search volume exceeds 10 million in the U.S. The quality-of-guidance supply is extremely limited — most practitioners entering this space don't have vetted 503A pharmacy relationships, protocol infrastructure, or compliance structure. ACG was among the first consulting firms to systematically launch peptide therapy clinics as a standalone category. The supply gap at the quality level is still significant in most U.S. markets.

Yes. ACG launches metabolic weight loss clinics as comprehensive practices — not GLP-1 dispensaries. The FDA and compounding regulatory environment in this category changes frequently. ACG tracks the current regulatory landscape, structures the practice correctly within the approved framework, and builds the full clinical infrastructure including Medical Director, pharmacy relationships, protocols, and patient acquisition strategy. The goal is a durable practice that doesn't depend on a single compound.

ACG clients report an average of $1.2 million in annual revenue. The highest-performing clinic in the ACG portfolio reported $3 million in annual revenue. These figures represent outcomes reported by clients and are not guarantees of income — individual results depend on market, patient volume, service mix, and operational execution. On a per-patient basis, ACG clinics typically structure treatment packages between $4,000 and $10,000 per patient depending on category and service mix.

Regenerative health, longevity, and aesthetic clinics operate almost entirely outside of insurance — patients pay directly. This eliminates insurance billing delays, reimbursement negotiations, and claim denials. Revenue is collected on the day of service. It also means higher per-patient revenue — patients are self-selecting for quality and paying for outcomes, not the minimum covered by their plan. The cash-pay model is one of the structural advantages that makes this category defensible.

Under a conservative patient ramp scenario, most ACG clinics target breakeven between months 3 and 6. This varies significantly by clinic type, market, and the pace of patient acquisition. Categories with high search demand — like hormone optimization and metabolic weight loss — typically ramp faster. Categories with longer patient acquisition cycles — like neurological wellness — take longer but often have higher lifetime patient value. ACG discusses the realistic breakeven window for your specific category on the strategy call.

Total capital requirements vary by clinic type, market, and facility size. The ACG consulting fee starts at a minimum investment discussed on the strategy call. Beyond the engagement fee, startup costs include lease deposits, buildout, equipment, initial supply orders, staffing, and working capital through to breakeven. ACG also partners with vetted lending providers to help clients access capital — ACG does not act as a lender. The full capital picture is mapped during the engagement before any commitments are made.

ACG partners with vetted lending providers to help clients access capital for clinic setup. ACG does not act as a lender and does not guarantee financing. The lending partner introductions are made as part of the engagement for clients who need access to capital. SBA loans, practice acquisition financing, and healthcare-focused lending programs are among the options ACG's lending partners can provide.

ACG has navigated clinic setup in 46 states. Each state has specific requirements around entity structure, physician ownership rules, clinical staff scope of practice, and licensing. ACG maps the compliance requirements for your specific state and clinic type before the engagement begins — so you don't discover a structural problem after you've already committed to a lease. This state-specific compliance navigation is one of the most valuable parts of the ACG engagement.

Some states have corporate practice of medicine (CPOM) laws that restrict non-physicians from owning medical practices outright. These requirements vary significantly — some states require a physician to be the sole or majority owner of the clinical entity, while others allow management service organization (MSO) structures that separate clinical ownership from business ownership. ACG has navigated both structures across dozens of states. If CPOM applies in your state, ACG builds the correct structure before you file anything — not after.

HIPAA compliance is built into every ACG clinic setup. This includes EMR selection with appropriate Business Associate Agreements, intake form design, patient communication infrastructure, and marketing platform compliance — including Meta CAPI integration and PHI-filtering for advertising. HIPAA violations are one of the most common and expensive problems in cash-pay health clinic operations. ACG builds the infrastructure correctly from the start.

Peptide therapy compliance centers on pharmacy sourcing (503A vs. 503B compounding pharmacies), the legal prescribability of specific peptide compounds, and the evolving FDA position on certain substances. ACG works exclusively with vetted 503A compounding pharmacy partners, structures prescribing through a properly supervised MD relationship, and monitors the regulatory landscape. The FDA's position on some peptides has shifted in recent years — ACG tracks this and adjusts clinic protocols accordingly.

ACG provides pre-negotiated pricing access to regenerative materials (exosomes, PRP, biologics), peptide compound sources through vetted 503A compounding pharmacies, IV therapy supplies and clinical consumables, aesthetic equipment, lab diagnostic partners, and EMR and operations technology. These relationships are built across 350+ engagements and are not available to independent operators at the same pricing. All introductions are included in the engagement — no additional charge.

ACG does not publish guaranteed savings figures because they vary by clinic type, service mix, and volume. What ACG can say: the rates ACG clients access on regenerative materials, clinical supplies, and equipment are materially lower than standard market rates for most independent operators. For most clinics, the difference compounds monthly and is one of the most direct financial benefits of the engagement. Specific supplier cost comparisons are reviewed on the strategy call for existing operators.

No. ACG is a consulting and advisory firm. There are no royalties, no brand licensing fees, no ongoing dependency, and no franchise agreement. After the ACG engagement is complete, you own your clinic, your brand name, your patient relationships, and all the equity you build — entirely. ACG empowers your independence. It does not create dependency.

A franchise means paying a franchise fee upfront, then paying ongoing royalties — typically 5–12% of gross revenue — indefinitely. You build equity in someone else's brand. Exit is constrained by franchise resale agreements. ACG is a one-time engagement fee. You own your brand outright. There are no royalties and no ongoing obligations. The equity you build belongs entirely to you. The flexibility to build the model that fits your market belongs to you. ACG provides the infrastructure — not the cage.

The key comparison points are: total 10-year cost of ownership (franchise fee + royalties + restrictions vs. one-time ACG fee), who owns the brand at exit, how much flexibility you have to adapt the model to your market, and what happens if the franchisor changes terms. Most ACG prospects who also evaluated franchise options chose ACG because the 10-year economics are significantly more favorable and the brand ownership question is simple — with ACG, you own it entirely.

Yes. ACG offers a dedicated telehealth consulting engagement for entrepreneurs who want to build a virtual regenerative health practice. The same core ACG system applies — Medical Director introduction, state licensing navigation, protocol development, HIPAA-compliant infrastructure, and marketing setup — without the physical location components. Telehealth is well-suited for hormone optimization, peptide therapy, and GLP-1 metabolic weight loss. Services that require in-person administration need a physical location.

Telehealth prescribing rules vary by state and by the specific compound or service being prescribed. Controlled substances — including testosterone — have additional federal requirements under the Ryan Haight Act. Post-COVID prescribing flexibilities continue to evolve. NP vs. MD prescribing authority differs significantly by state in a telehealth context. ACG tracks all of this and maps the specific regulatory landscape for your target states and service focus before the engagement begins.

Yes. Many ACG clients build the telehealth practice first — to validate patient demand, build brand presence, and establish cash flow — then open a physical location in their primary market. ACG builds the telehealth infrastructure with that expansion in mind. The systems carry over cleanly when you add a physical location.

Yes. ACG has a dedicated existing clinic growth and optimization engagement. ACG works with chiropractors, med spas, weight loss clinics, wellness centers, hormone clinics, IV therapy practices, and any cash-pay or hybrid operation. The engagement covers supplier access at pre-negotiated rates, clinical and front-office training, operations review, and marketing audit. Many existing operators find that supplier costs alone are a significant opportunity.

Yes. This is one of the most common reasons existing operators work with ACG. Adding peptide therapy, hormone optimization, IV therapy, GLP-1 protocols, or joint and musculoskeletal regenerative services to an existing practice requires the right service category for your patient base, supplier access, clinical training, and compliance structure. ACG provides all four. The existing patient base is the most underutilized asset in most practices.

Before recommending anything, ACG reviews your current operation thoroughly — supplier costs against ACG network rates, marketing performance against category benchmarks, staff training gaps, and operational efficiency. The assessment produces specific, prioritized findings — not a generic report. If ACG doesn't find at least three specific, actionable opportunities, they will tell you that directly. Pricing for the engagement is discussed on the strategy call after the scope is understood.

The ACG launch engagement includes brand awareness campaign setup, local SEO activation across 100+ business directories, and paid advertising infrastructure through compliant frameworks. Marketing execution services are provided by United One Media Group, a separate entity from ACG. ACG builds the marketing infrastructure and strategy — execution is handled by the media partner. Post-launch marketing diagnosis is included in the 60-day advisory period.

Major ongoing costs include lease and facility costs, clinical staff compensation, medical supply costs (where ACG's pre-negotiated supplier pricing provides a material advantage), Medical Director fees, EMR and technology subscriptions, marketing spend, and general business operating costs. There are no ongoing fees to ACG after the engagement is complete. The full operating cost picture is modeled as part of the ACG engagement so you understand the economics before you open.

Many ACG clients open a second location once the first is established and cash-flow positive — often within 12–18 months of the first launch. Others expand by adding service categories, building out a telehealth practice alongside the physical location, or moving into adjacent markets. ACG offers continued advisory support for growth-phase clients. Because you own your brand entirely, expansion is on your terms — no franchise approval required, no royalty structure to negotiate around.